E
Eduardo Lazcano-Ponce
Researcher at Universidad Veracruzana
Publications - 360
Citations - 13777
Eduardo Lazcano-Ponce is an academic researcher from Universidad Veracruzana. The author has contributed to research in topics: Population & Cervical cancer. The author has an hindex of 59, co-authored 344 publications receiving 12716 citations.
Papers
More filters
Journal ArticleDOI
Epidemiology and molecular pathology of gallbladder cancer.
Eduardo Lazcano-Ponce,Juan Miquel,Nubia Muñoz,Rolando Herrero,Catterina Ferrecio,Ignacio Ivan Wistuba,Patricia Alonso de Ruiz,Gerardo Aristi Urista,Flavio Nervi +8 more
TL;DR: The worldwide geographical distribution of gallbladder cancer is reported, the main etiologic hypotheses are reviewed, and some comments on perspectives for prevention are provided.
Journal ArticleDOI
Variations in the age‐specific curves of human papillomavirus prevalence in women worldwide
Silvia Franceschi,Rolando Herrero,Gary M. Clifford,Peter J.F. Snijders,Annie Arslan,Pham Thi Hoang Anh,F. Xavier Bosch,Catterina Ferreccio,Nguyen Trong Hieu,Eduardo Lazcano-Ponce,Elena Matos,Mónica Molano,You-Lin Qiao,R. Rajkumar,Guglielmo Ronco,Silvia de Sanjosé,Hai-Rim Shin,Sukhon Sukvirach,Jaiye O. Thomas,Chris J.L.M. Meijer,Nubia Muñoz +20 more
TL;DR: The substantial differences observed in age‐specific curves of HPV prevalence between populations may have a variety of explanations, however, underline that great caution should be used in inferring the natural history of HPV from age-specific prevalences.
Journal ArticleDOI
Epidemiology of HPV infection among Mexican women with normal cervical cytology.
Eduardo Lazcano-Ponce,Rolando Herrero,Nubia Muñoz,Aurelio Cruz,Keerti V. Shah,Patricia Alonso,Pilar Hernández,Jorge Salmerón,Mauricio Hernández +8 more
TL;DR: Previous findings of a second peak of high‐risk HPV infections in postmenopausal women are confirmed, in this case with a clear predominance of cancer‐associated HPV types.
Journal ArticleDOI
Comprehensive control of human papillomavirus infections and related diseases.
F. Xavier Bosch,Thomas R. Broker,David Forman,Anna-Barbara Moscicki,Maura L. Gillison,John Doorbar,Peter L. Stern,Margaret Stanley,Marc Arbyn,Mario Poljak,Jack Cuzick,Philip E. Castle,John T. Schiller,Lauri E. Markowitz,William A. Fisher,Karen Canfell,Lynette Denny,Eduardo L. Franco,Marc Steben,Mark A. Kane,Mark Schiffman,Chris J.L.M. Meijer,Rengaswamy Sankaranarayanan,Xavier Castellsagué,Jane J. Kim,Maria Brotons,Laia Alemany,Ginesa Albero,Mireia Diaz,Silvia de Sanjosé,Ahti Anttila,Lawrence Banks,Christine Bergeron,Jerome L. Belinson,Johannes Berkhof,Ignacio G. Bravo,Freddie Bray,Julia M.L. Brotherton,Laia Bruni,Ann N. Burchell,Anil K. Chaturvedi,Harrell W. Chesson,Myriam Chevarie-Davis,Heather Cubie,Shelley L. Deeks,Catherine de Martel,Joakim Dillner,Mark H. Einstein,Jacques Ferlay,Alison Nina Fiander,Silvia Franceschi,Suzanne M. Garland,Anna R. Giuliano,Marc T. Goodman,Patti E. Gravitt,Ian N. Hampson,Isabelle Heard,Thomas Iftner,Sandra D. Isidean,Christina Jensen,Jose Jeronimo,Walter Kinney,Henry C Kitchener,Susanne K. Kjaer,Boŝtjan J. Kocjan,George Koliopoulos,Shalini L Kulasingam,Charles J.N. Lacey,D. Scott LaMontagne,Eduardo Lazcano-Ponce,Attila T. Lorincz,Joannie Lortet-Tieulent,Pontus Naucler,Gina Ogilvie,Joel M. Palefsky,Julian Peto,Ligia A. Pinto,Martyn Plummer,You-Lin Qiao,Wim Quint,Guglielmo Ronco,Steve Schwartz,Beatriz Serrano,Jennifer S. Smith,Peter J.F. Snijders,Isabelle Soerjomataram,Bettie M. Steinberg,Mark H. Stoler,Anne Szarewski,Connie Trimble,Vivien Tsu,Pierre Van Damme,Sjoerd H. van der Burg,Andrea Vicari,Jérôme Vignat,Magnus von Knebel Doeberitz,Alex Vorsters,Susan A. Wang,Scott Wittet +98 more
TL;DR: There must be ongoing efforts including international advocacy to achieve widespread-optimally universal-implementation of HPV prevention strategies in both developed and developing countries.
Journal ArticleDOI
Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial.
Keith S. Reisinger,Stan L. Block,Eduardo Lazcano-Ponce,Rudiwilai Samakoses,Mark T. Esser,Joanne Erick,Derek Puchalski,Katherine E.D. Giacoletti,Heather L. Sings,Suzanne Lukac,Frances B. Alvarez,Eliav Barr +11 more
TL;DR: In 9- to 15-year-old adolescents, the quadrivalent vaccine was generally well tolerated and induced persistent anti-HPV serologic responses in the majority of subjects for at least 12 months following completion of a three-dose regimen.